Highlights a rare case of primary paraesophageal Ewing's sarcoma with EWSR1/ERG fusion that was refractory to chemotherapy, underscoring the need for improved systemic therapy options.
This is the authors' abstract. We don't add key points for this paper.
Ewing's sarcoma is a rare and highly aggressive cancer most frequently arising in people under 20 years of age. We report an uncommon case of primary paraesophageal Ewing's sarcoma in a 25-year-old male harboring the infrequent EWSR1/ERG fusion transcript with multiple splice variants coexisting in the same tumor. The patient was totally refractory to chemotherapy and died 17 months after diagnosis. We underscore the need for better understanding of the molecular pathogenesis of the disease and improved systemic therapy options.
Answers are grounded in this paper and cite their sources.
Rare Ewing sarcoma case signals chemotherapy shortfalls; leaves open need for fusion-directed systemic therapies.
No takes yet. Share an insight, caveat, or question.
Tarazona et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: